COVID-19 Proteins Just Released

New England Peptide / Peptides International just made available new recombinant proteins related to the COVID-19 (Coronavirus).

These, along will other coronavirus strains and related items, are available through this link. We would also like you alert you to our brand new page: The COVID-19 Information Station, designed to be an aggregator of all our related COVID-19 info.

Some background*:

A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the city of Wuhan, Hubei province of China on December 2019.

The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity, thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans.

RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.

 The new products with their respective links are:

  • nCoV-S1
    Novel Coronavirus 2019-nCoV Spike Glycoprotein-S1, Recombinant

  • nCoV-S2
    Novel Coronavirus 2019-nCoV Spike Glycoprotein-S2, Recombinant

  • CoV-2019 Nucleocapsid
    Coronavirus 2019 Nucleocapsid Recombinant

  • CoV Spike E-Mosaic
    Coronavirus 2019 Spike E-Mosaic Recombinant

  • CoV N-Mosaic
    Coronavirus 2019 Nucleocapsid Mosaic Recombinant

If you need a peptide derived from the SARS-CoV-2 S protein or any other region or a fusion peptide, please let us know and we would be happy to help with a custom peptide synthesis.

Related topics: ACE2, Angiotensin, Angiotensin TrypTides, Bradykinin, Bradykinin TrypTides, Influenza Matrix Protein M1 (58-66),  camostat mesylate, custom antibodies, OVA Peptide (257-264), putative orf1ab polyprotein (3233-3247) [SARS coronavirus]

*background content supplied by ProSpec


"THANKS AGAIN for all the intellectual support that NEP has provided to us over the last year. My colleagues have been overwhelmingly impressed with the quality of service and level of thought that you have put into researching and thinking about our particular peptide and antibody production needs. The level of scholarship went well beyond what we expected from any peptide and antibody company, and was crucial in shaping our decisions. It has truly been a pleasure corresponding with you."
Cliff N. PhD - Lawrence Berkeley National Laboratory